Rizatriptan STADA

What Is Rizatriptan STADA and What Is It Used For?

Rizatriptan STADA belongs to a class of medicines known as selective 5-HT1B/1D serotonin receptor agonists, commonly referred to as triptans. This medication has been specifically developed for the treatment of the headache phase of migraine attacks and should be taken as soon as migraine symptoms begin. It is important to understand that Rizatriptan STADA is not a preventive medicine — it does not reduce the frequency of migraine attacks but instead provides relief during an active episode.

The mechanism of action of rizatriptan involves two key pharmacological effects. First, it binds to 5-HT1B receptors on intracranial blood vessels, causing vasoconstriction (narrowing) of the dilated arteries that contribute to migraine pain. During a migraine, blood vessels surrounding the brain become swollen and inflamed, and by constricting these vessels, rizatriptan helps relieve the characteristic throbbing headache. Second, it activates 5-HT1D receptors on sensory nerve endings of the trigeminal nerve, inhibiting the release of pro-inflammatory neuropeptides such as calcitonin gene-related peptide (CGRP) and substance P. This dual action addresses both the vascular and neurogenic components of migraine pathophysiology.

Clinical studies have demonstrated that rizatriptan provides meaningful headache relief in approximately 67–77% of patients within 2 hours of taking a dose, with many patients experiencing significant improvement within 30 minutes. The medication is effective against migraine with or without aura and also helps alleviate associated symptoms such as nausea, photophobia (sensitivity to light), and phonophobia (sensitivity to sound).

Rizatriptan STADA is manufactured by STADA Arzneimittel AG, a well-established European pharmaceutical company. It is a generic formulation containing rizatriptan as the active ingredient in the form of rizatriptan benzoate. The tablets are available in two strengths: 5 mg and 10 mg. The medication is bioequivalent to the original branded rizatriptan product, meaning it delivers the same therapeutic effect at the same rate and extent of absorption.

It is critical to note that rizatriptan should only be used when a definitive diagnosis of migraine has been made by a healthcare professional. The medication should not be used to treat other types of headache, including tension-type headache, cluster headache, or headaches caused by other underlying conditions. If you are uncertain about your diagnosis, consult your doctor before using this medicine.

What Should You Know Before Taking Rizatriptan STADA?

Before starting treatment with Rizatriptan STADA, it is essential to discuss your complete medical history with your prescribing physician. Several conditions and circumstances can make the use of this medication unsafe or require special precautions. The following information will help you understand whether rizatriptan is appropriate for you and what steps your healthcare provider may need to take to ensure safe use.

Contraindications

• You are allergic to rizatriptan benzoate, menthol, or any other ingredient in the tablets (see the Ingredients section below for the full list).
• You have moderate or severe hypertension (high blood pressure) or mild hypertension that is not being treated with medication.
• You have or have ever had heart disease, including coronary artery disease, a previous heart attack (myocardial infarction), or chest pain (angina pectoris), or if you have experienced symptoms suggestive of heart disease.
• You have severe liver or kidney disease.
• You have had a stroke (cerebrovascular accident) or a transient ischaemic attack (TIA, sometimes called a mini-stroke).
• You have peripheral vascular disease (problems with blood circulation in your limbs).
• You are currently taking MAO inhibitors such as moclobemide, phenelzine, tranylcypromine, or pargyline (medicines used for depression), or linezolid (an antibiotic), or if it has been less than two weeks since you stopped taking an MAO inhibitor.
• You are currently taking ergotamine-type medicines such as ergotamine or dihydroergotamine for migraine treatment, or methysergide for migraine prevention.
• You are taking another triptan such as sumatriptan, naratriptan, or zolmitriptan.

Warnings and Precautions

Talk to your doctor or pharmacist before taking Rizatriptan STADA if any of the following situations apply to you. Your doctor may need to perform additional assessments or monitor you more closely:

• You have risk factors for cardiovascular disease: high blood pressure, diabetes, smoking or use of nicotine replacement products, a family history of heart disease, being a man over 40 years of age, or being a postmenopausal woman. Your doctor may wish to perform a cardiovascular evaluation before prescribing rizatriptan.
• You have kidney or liver problems — a lower dose (5 mg) may be required.
• You have a particular type of heart rhythm abnormality known as bundle branch block.
• You have a history of allergies, or you have previously experienced angioedema (swelling of the face, lips, tongue, or throat causing difficulty breathing or swallowing).
• Your headache is accompanied by dizziness, difficulty walking, coordination problems, or weakness in your arms or legs — these symptoms may indicate a condition other than migraine.
• You use products containing St. John’s wort (Hypericum perforatum), which may increase the risk of serotonin syndrome.
• You take SSRIs (selective serotonin reuptake inhibitors) such as sertraline, escitalopram, or fluoxetine, or SNRIs (serotonin-noradrenaline reuptake inhibitors) such as venlafaxine or duloxetine for depression — combining these with rizatriptan may increase the risk of serotonin syndrome.
• You have experienced brief episodes of chest pain or chest pressure after previous triptan use.

Pregnancy and Breastfeeding

If you are pregnant, breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Pregnancy: The available evidence on rizatriptan use during the first trimester of pregnancy does not suggest an increased risk of birth defects. However, the safety of rizatriptan when used after the first trimester has not been adequately established. Your doctor will weigh the potential benefits against the possible risks before recommending this medication during pregnancy.

Breastfeeding: Rizatriptan may pass into breast milk. To minimise your infant’s exposure, you should avoid breastfeeding for at least 24 hours after taking a dose. Discuss feeding options with your healthcare provider if you need to use rizatriptan while nursing.

Special Populations

Elderly patients (over 65 years): There are no complete studies on the safety and efficacy of rizatriptan in patients over 65 years of age. Use in this population should be guided by careful individual risk assessment by a physician.

Children and adolescents (under 18 years): The use of Rizatriptan STADA in children and adolescents under 18 years of age is not recommended due to insufficient data on safety and efficacy in this age group.

Driving and Operating Machinery

You may feel drowsy or dizzy when taking Rizatriptan STADA. Additionally, migraine itself can impair your ability to concentrate. If you experience these effects, do not drive, operate machinery, or engage in activities requiring full mental alertness until you have recovered. You are responsible for assessing your own fitness to perform these tasks.

How Does Rizatriptan STADA Interact with Other Drugs?

Drug interactions can significantly affect how rizatriptan works or increase the risk of dangerous side effects. Always inform your doctor or pharmacist about all medicines you are taking, have recently taken, or might take, including prescription medicines, over-the-counter products, and herbal supplements. The interactions described below are clinically important and should be carefully considered.

Major Interactions (Contraindicated Combinations)

Important Interactions Requiring Caution

Food and Alcohol

Taking Rizatriptan STADA after a meal may delay the onset of action. Although the medication can be taken with food, it is more effective when taken on an empty stomach. There are no specific contraindications regarding alcohol, but alcohol may worsen migraine symptoms and impair your ability to assess the medication’s effectiveness.

What Is the Correct Dosage of Rizatriptan STADA?

Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Rizatriptan STADA should be taken as early as possible after the onset of a migraine headache. It should not be used to prevent attacks or to treat headache aura without subsequent headache development.

Adults

If Your Migraine Returns

In some patients, migraine symptoms may recur within 24 hours after initial relief. If your migraine returns, you may take a second dose of Rizatriptan STADA, provided that at least 2 hours have passed since your first dose. Do not exceed a total of 2 doses in any 24-hour period.

If the First Dose Does Not Work

If the first dose of Rizatriptan STADA does not provide relief within 2 hours, do not take a second dose for the same migraine attack. A second dose is unlikely to be effective for a non-responsive episode. However, rizatriptan will likely work for future migraine attacks even if it did not relieve a particular episode. If your migraines frequently do not respond to rizatriptan, discuss alternative treatment options with your doctor.

Missed Dose

Rizatriptan is used on an as-needed basis to treat individual migraine attacks, so there is no regular dosing schedule and therefore no concept of a missed dose. Simply take the medication when you experience a migraine attack, following the dosage instructions above.

Overdose

Symptoms of overdose may include dizziness, drowsiness, vomiting, fainting, and slow heart rate (bradycardia). There is no specific antidote for rizatriptan overdose, and treatment is supportive. Clinical monitoring should continue for at least 12 hours, or longer if symptoms persist.

How to Take the Tablets

Rizatriptan STADA tablets should be swallowed whole with a glass of water. The tablets can be taken with or without food, although taking them on an empty stomach may lead to a faster onset of action. Do not crush, chew, or split the tablets unless instructed to do so by your doctor.

What Are the Side Effects of Rizatriptan STADA?

Like all medicines, Rizatriptan STADA can cause side effects, although not everybody gets them. The side effects listed below are based on clinical trial data and post-marketing surveillance reports. Most side effects are mild to moderate and resolve without specific treatment.

If you experience any side effects, including those not listed above, talk to your doctor or pharmacist. You can also report side effects directly to your national medicines regulatory authority to help monitor the ongoing safety of this medicine.

How Should You Store Rizatriptan STADA?

Proper storage of your medication is essential to maintain its safety and effectiveness throughout its shelf life. Follow these guidelines to ensure your Rizatriptan STADA tablets remain in optimal condition:

• Keep out of the sight and reach of children. Store the medication in a secure location that children cannot access.
• Store in the original packaging. The aluminium/aluminium blister packaging is designed to protect the tablets from moisture. Do not transfer tablets to another container.
• Check the expiry date. Do not use this medicine after the expiry date stated on the blister and carton after “EXP”. The expiry date refers to the last day of that month.
• No special temperature requirements. Store at room temperature, away from excessive heat and direct sunlight.
• Disposal: Do not throw medicines into household waste or wastewater. Return unused or expired medicines to your pharmacist for safe disposal. These measures help protect the environment.

What Does Rizatriptan STADA Contain?

Active Ingredient

The active ingredient is rizatriptan, present in the form of rizatriptan benzoate:

• Rizatriptan STADA 5 mg tablet: contains 5 mg rizatriptan (equivalent to 7.265 mg rizatriptan benzoate)
• Rizatriptan STADA 10 mg tablet: contains 10 mg rizatriptan (equivalent to 14.53 mg rizatriptan benzoate)

Inactive Ingredients (Excipients)

The other ingredients are: mannitol, maltodextrin, microcrystalline cellulose, crospovidone type A, saccharin sodium, colloidal anhydrous silica, magnesium stearate, and menthol flavouring (containing maltodextrin, natural menthol, and modified maize starch).

Appearance and Pack Sizes

5 mg tablets: Round, flat, white to off-white tablets, 8 mm in diameter with bevelled edges.

10 mg tablets: Round, flat, white to off-white tablets, 10 mm in diameter with bevelled edges.

Rizatriptan STADA is available in aluminium/aluminium blister packs containing 2, 3, 6, 12, or 18 tablets. Not all pack sizes may be marketed in your country.

References

This article is based on the following evidence-based sources and international medical guidelines:

1. European Medicines Agency (EMA). Summary of Product Characteristics: Rizatriptan. European public assessment reports. Accessed January 2026.
2. U.S. Food and Drug Administration (FDA). Maxalt (rizatriptan benzoate) Prescribing Information. Updated 2024.
3. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. The Lancet. 2001;358(9294):1668–1675. doi:10.1016/S0140-6736(01)06711-3
4. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics, and efficacy. Drugs. 2000;60(6):1259–1287.
5. World Health Organization (WHO). WHO Model List of Essential Medicines – 23rd List. 2023.
6. National Institute for Health and Care Excellence (NICE). Clinical Knowledge Summaries: Migraine. Updated 2024.
7. British National Formulary (BNF). Rizatriptan monograph. Accessed January 2026.
8. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.
9. Dodick DW. Triptan nonresponder studies: implications for clinical practice. Headache. 2005;45(2):156–162.
10. Diener HC, Holle-Lee D, Nägel S, et al. Treatment of migraine attacks and prevention of migraine: Guidelines by the German Migraine and Headache Society and the German Society of Neurology. Clinical and Translational Neuroscience. 2019;3(1):1–40.

Medical Editorial Team

This article has been written and medically reviewed by the iMedic Medical Editorial Team, comprising licensed specialist physicians with expertise in neurology, clinical pharmacology, and headache medicine. All content follows the GRADE evidence framework and adheres to international clinical guidelines from the WHO, EMA, FDA, and NICE.

For questions about this article or to report an error, please visit our contact page. To learn more about our review process, see our editorial standards.